Gujarat Themis Biosyn Q1 PAT Up 22% YoY

Gujarat Themis Biosyn Limited submitted an Investor Presentation for Q1 FY2026-27 ended 30th June, 2026 under Regulation 30 of SEBI LODR Regulations.

Dr. Sachin Patel, Managing Director, commented on the results:

The company began the new financial year on a strong note with continued growth momentum
Healthy sales volumes reflected stable market demand, boosting topline and margins
Significant progress in inorganic expansion through two major acquisitions
New R&D and API units are operational; fermentation facility development complete
18 MW hybrid power plant in Gujarat underway for captive consumption to reduce power costs and carbon footprint

Income from Operations: ₹43.79 crore (vs ₹35.87 crore in Q1 FY26), up 22.07%
EBITDA: ₹20.79 crore (vs ₹13.92 crore), up 49.37%
EBITDA Margin: 47.48% (vs 38.81%), improved 867 bps
PAT: ₹11.07 crore (vs ₹9.06 crore), up 22.13%
PAT Margin: 25.27% (vs 25.26%), improved 1 bp
EPS: ₹1.02 (vs ₹0.83), up 22.89%

Income from Operations: ₹165.82 crore (vs ₹150.80 crore in FY25), up 9.96%
EBITDA: ₹75.53 crore (vs ₹68.84 crore), up 9.71%
EBITDA Margin: 45.55% (vs 45.65%), declined 10 bps
PAT: ₹46.68 crore (vs ₹48.77 crore), down 4.29%
PAT Margin: 28.15% (vs 32.34%), declined 419 bps
EPS: ₹4.28 (vs ₹4.48), down 4.46%

Total Equity & Liabilities: ₹503.43 crore (vs ₹301.31 crore as on 31st March 2025)
Shareholders Funds: ₹287.77 crore (vs ₹248.38 crore)
Non Current Liabilities: ₹136.51 crore (vs ₹32.37 crore)
Current Liabilities: ₹79.15 crore (vs ₹20.56 crore)
Total Assets: ₹503.43 crore (vs ₹301.31 crore)
Non Current Assets: ₹414.64 crore (vs ₹249.34 crore)
Current Assets: ₹88.78 crore (vs ₹51.97 crore)
Property Plant & Equipment: ₹286.92 crore (vs ₹40.58 crore)
Capital Work in Progress: ₹121.13 crore (vs ₹184.41 crore)
Trade Receivables: ₹60.92 crore (vs ₹31.24 crore)
Cash & Cash Equivalents: ₹3.12 crore (vs ₹11.69 crore)

1. MicroBiopharm Japan Co., Ltd. Acquisition

Deal Value: JPY 21.5 billion (~₹1,300 crore)
Stake: 100% via wholly owned SPV in Japan
Seller: T Capital Partners (Japan-based PE fund)
Expected Close: Q2 FY2027 (subject to regulatory approvals)
Target Revenue (FY26E): JPY 9.5 billion (~₹575 crore)
Strategic Benefits:
Expands API and intermediates portfolio across oncology, immunosuppressants, and peptides
Provides access to Top 6 global pharma customers with 20+ year relationships
40% revenues from outside Japan across Asia, Europe & North America
Adds proprietary P450 enzyme library, Plasmid DNA, ADC Conjugation technologies
Accelerates transition to global fermentation-based CDMO

2. Sanofi Product Portfolio Acquisition

Deal Value: ~€158 million
Funding: Debt and equity mix
Portfolio Revenue (FY2025): ~€62 million
Assets: 13 established global brands across 55+ countries
Therapeutic Focus: Tuberculosis & anti-infectives
Key Molecules: Levofloxacin, Rifampicin, Rifapentine (WHO Essential & EU Critical Medicines)
Structure: Asset acquisition (Brands + Marketing Authorizations + Dossiers + Inventory)
Retail Contribution: ~70% of revenue
Expected Impact: EPS accretive with healthy gross margins; additional upside from API integration and cost optimization

Current Product Portfolio: Rifamycin intermediates for manufacturing Rifampicin and Rifaximin antibiotics
Production Capacity: Up to 990 KL fermentation capacity
Expansion Initiatives:
New R&D unit commissioned as per international standards
Commercial operations begun at new API unit
Fermentation capacity expansion for new products
Focus on domestic and export market expansion
Manufacturing: State-of-art facilities at Vapi, Gujarat using aerobic bacteria fermentation
ESG Initiative: 18 MW hybrid wind-solar power project for captive consumption to reduce grid dependence and carbon footprint